LAGEVRIO 200mg hard capsules medication leaflet

J05AB18 molnupiravir • Antiinfectives for systemic use | Direct acting antivirals | Nucleosides and nucleotides excl. reverse transcriptase inhibitors

Molnupiravir is an antiviral medication used for the treatment of COVID-19 in patients with mild to moderate disease who are at high risk of progressing to severe illness. It works by inhibiting the replication of the SARS-CoV-2 virus, thereby reducing viral load.

The medication is taken orally, usually twice daily for five days. It is effective in reducing the risk of hospitalization and death in high-risk patients.

Side effects may include nausea, diarrhea, dizziness, and headache. Currently, its use is limited to certain patient groups, and its long-term safety is still under investigation.

Consult your doctor to discuss whether Molnupiravir is suitable for you. It is important to follow the prescribed dosage and adhere to all medical recommendations.

General data about LAGEVRIO 200mg

Substance: molnupiravir

Commercial code: W530950089

Concentration: 200mg

Pharmaceutical form: hard capsules

Quantity: 40

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: Merck Sharp & Dohme B.V. - OLANDA

Holder: Merck Sharp & Dohme (UK) Limited - UK

Number: PLGB 53095/0089

PDF icon Leaflet
PDF icon Leaflet patient
Published: 04/11/2011